Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GelStat Migraine is an over-the-counter homeopathic sublingual gel indicated for the acute treatment of migraine headaches. Developed by GelStat Corporation, the formulation contains a combination of feverfew (*Tanacetum parthenium*) and ginger (*Zingiber officinale*). These active ingredients are traditionally recognized for their anti-inflammatory properties, specifically through the inhibition of prostaglandin synthesis and inflammatory mediators like cyclooxygenase and lipoxygenase. The sublingual delivery system is designed to allow for rapid absorption into the systemic circulation via the oral mucosa, bypassing first-pass metabolism and providing faster relief compared to oral tablets. It is intended for use at the earliest signs of migraine onset during the mild pain phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GelStat Migraine.